Q1 EPS Forecast for Corcept Therapeutics Reduced by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Investment analysts at Zacks Research dropped their Q1 2025 earnings estimates for Corcept Therapeutics in a report released on Wednesday, December 18th. Zacks Research analyst K. Das now forecasts that the biotechnology company will post earnings of $0.27 per share for the quarter, down from their prior forecast of $0.29. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.34 EPS, Q3 2025 earnings at $0.42 EPS, Q4 2025 earnings at $0.53 EPS, Q2 2026 earnings at $0.55 EPS, Q3 2026 earnings at $0.71 EPS and FY2026 earnings at $2.41 EPS.

A number of other brokerages have also issued reports on CORT. HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Corcept Therapeutics in a research note on Thursday, October 31st. Truist Financial raised their target price on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. Sandler O’Neill reaffirmed a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. StockNews.com lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. Finally, Piper Sandler boosted their price objective on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, September 18th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $65.25.

Corcept Therapeutics Price Performance

Shares of NASDAQ:CORT opened at $51.40 on Friday. The company has a market cap of $5.39 billion, a P/E ratio of 40.79 and a beta of 0.51. The business has a fifty day simple moving average of $53.83 and a 200-day simple moving average of $41.92. Corcept Therapeutics has a 52 week low of $20.84 and a 52 week high of $62.22. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.14. The firm had revenue of $182.55 million for the quarter, compared to analyst estimates of $171.97 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. Corcept Therapeutics’s revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.28 earnings per share.

Hedge Funds Weigh In On Corcept Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. lifted its position in shares of Corcept Therapeutics by 40.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,223,781 shares of the biotechnology company’s stock worth $56,637,000 after purchasing an additional 352,947 shares in the last quarter. FMR LLC increased its stake in Corcept Therapeutics by 24.6% during the 3rd quarter. FMR LLC now owns 1,363,922 shares of the biotechnology company’s stock worth $63,122,000 after buying an additional 269,074 shares during the period. M&G PLC purchased a new stake in Corcept Therapeutics during the 3rd quarter worth $11,173,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Corcept Therapeutics by 20.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 859,563 shares of the biotechnology company’s stock worth $39,781,000 after buying an additional 143,507 shares in the last quarter. Finally, abrdn plc boosted its position in Corcept Therapeutics by 27.1% in the 3rd quarter. abrdn plc now owns 666,952 shares of the biotechnology company’s stock valued at $30,867,000 after buying an additional 142,310 shares during the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Insider Activity at Corcept Therapeutics

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $59.46, for a total value of $130,812.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Gary Charles Robb sold 11,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $46.28, for a total value of $509,080.00. Following the transaction, the insider now owns 22,772 shares in the company, valued at approximately $1,053,888.16. This represents a 32.57 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,811 shares of company stock worth $1,341,360. Company insiders own 20.50% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.